These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 24876747)

  • 1. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
    Tang CM; Yau TO; Yu J
    World J Gastroenterol; 2014 May; 20(20):6262-78. PubMed ID: 24876747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
    Juszczyk J; Boroń-Kaczmarska A; Cianciara J; Flisiak R; Gładysz A; Halota W; Kryczka W; Malkowski P; Pawlowska M; Simon K;
    Pol Merkur Lekarski; 2010 Aug; 29(170):103-6. PubMed ID: 20842822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Rijckborst V; Sonneveld MJ; Janssen HL
    Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
    Shan C; Yin GQ; Wu P
    J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the treatment of chronic hepatitis B.
    Hadziyannis SJ
    Expert Opin Biol Ther; 2006 Sep; 6(9):913-21. PubMed ID: 16918258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Hadziyannis SJ
    Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
    Petersen J; Buti M
    Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
    Galati G; De Vincentis A; Vespasiani-Gentilucci U; Gallo P; Vincenti D; Solmone MC; Dell'Unto C; Picardi A
    BMC Gastroenterol; 2014 May; 14():94. PubMed ID: 24885182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 Mar; 39(6):629-37. PubMed ID: 24467455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.